Shifting patterns of inhaled antibiotic use in cystic fibrosis

被引:48
|
作者
Moskowitz, Samuel M. [1 ]
Silva, Stefanie J. [2 ]
Mayer-Hamblett, Nicole [1 ]
Pasta, David J. [2 ]
Mink, David R. [2 ]
Mabie, Jenny A. [3 ]
Konstan, Michael W. [4 ]
Wagener, Jeffrey S. [3 ,5 ]
机构
[1] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA
[2] ICON Clin Res, San Francisco, CA USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA
[5] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA
关键词
cystic fibrosis; Pseudomonas aeruginosa; airway infection; antibiotics; tobramycin; colistin; inhaled therapy; epidemiology;
D O I
10.1002/ppul.20873
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Rationale: Antibiotic inhalation has become widely accepted as a standard treatment for cystic fibrosis (CF) airway infection. We assessed the prevalence and context of inhaled antibiotic use in the North American CIF population. Our working hypothesis was that a shift from acute to chronic use of inhaled antibiotics has coincided with increased prevalence of use among CF patients. Methods: Descriptive statistics were collected for 30,833 patients enrolled in the Epidemiologic Study of CF (ESCF) during 1996 through 2005. A multivariate analysis was performed on data from a subgroup of 18,021 patients enrolled in ESCF during 2003 through 2005. Results: The prevalence of inhaled antibiotic use in the North American CF population increased during 1996 through 2005 due to increased chronic use, while acute use to treat pulmonary exacerbations decreased. In 2005, 50% of CF patients used inhaled tobramycin and 9% used inhaled colistin chronically; most of the latter used both agents concurrently Airway obstruction severity and airway infection status were predictors of inhaled antibiotic use. Conclusions: Increased chronic use and decreased acute use of inhaled antibiotics presumably reflect a shift toward more proactive management of airway infections in the North American CIF population. The effects of these usage patterns on long-term clinical outcomes and emergence of antibiotic-resistant Pseudomonas aeruginosa strains warrant further study.
引用
收藏
页码:874 / 881
页数:8
相关论文
共 50 条
  • [1] Use of Inhaled Tobramycin in Cystic Fibrosis
    Shteinberg, Michal
    Elborn, J. Stuart
    ADVANCES IN THERAPY, 2015, 32 (01) : 1 - 9
  • [2] Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis
    Wagener, Jeffrey S.
    Rasouliyan, Lawrence
    VanDevanter, Donald R.
    Pasta, David J.
    Regelmann, Warren E.
    Morgan, Wayne J.
    Konstan, Michael W.
    PEDIATRIC PULMONOLOGY, 2013, 48 (07) : 666 - 673
  • [3] Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany
    Naehrig, S.
    Schulte-Hubbert, B.
    Hafkemeyer, S.
    Hammermann, J.
    Dumke, M.
    Sieber, S.
    Naehrlich, L.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2023, 80
  • [4] Inhaled Interventions in Cystic Fibrosis: Mucoactive and Antibiotic Therapies
    Hurt, Katharine
    Bilton, Diana
    RESPIRATION, 2014, 88 (06) : 441 - 448
  • [5] Use of Inhaled Tobramycin in Cystic Fibrosis
    Michal Shteinberg
    J. Stuart Elborn
    Advances in Therapy, 2015, 32 : 1 - 9
  • [6] Antibiotic use in cystic fibrosis
    Kelly, H. William
    Lovato, Carol
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (7-8) : 1424 - 1435
  • [7] USE OF INHALED TOBRAMYCIN IN PATIENTS WITH CYSTIC FIBROSIS
    Chermensky, A. G.
    Gembitskaya, M. E.
    TERAPEVTICHESKII ARKHIV, 2010, 82 (08) : 76 - 78
  • [8] Inhaled antibiotic use is associated with Scedosporium/Lomentospora species isolation in cystic fibrosis
    Hong, Gina
    Lechtzin, Noah
    Hadjiliadis, Denis
    Kawut, Steven M.
    PEDIATRIC PULMONOLOGY, 2019, 54 (02) : 133 - 140
  • [9] Development of the First Inhaled Antibiotic for the Treatment of Cystic Fibrosis
    Rose, Lynn M.
    Neale, Richard
    SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (63)
  • [10] Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis
    Antoniu, Sabina
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2015, 13 (07) : 897 - 905